PATIENT: PT-2024-001 (SYNTHETIC - NOT REAL)
DOCUMENT TYPE: MD Oncology Note — Follow Up Visit
VISIT NUMBER: 2
DATE: 2024-03-15
PHYSICIAN: Dr. Amanda Singh (SYNTHETIC)

INTERVAL HISTORY:
Patient returns with completed staging workup.
Tolerating current medications well.
No new symptoms. Mild anxiety about diagnosis.

STAGING RESULTS REVIEWED:
PET-CT: Hypermetabolic left breast mass confirmed.
Left axillary lymph nodes FDG avid (3 nodes).
No distant metastatic disease identified.
No bone lesions. No liver lesions. No lung nodules.

MRI LEFT BREAST:
Mass measures 2.3cm on MRI (slightly larger than US).
No additional foci of disease in either breast.
Skin involvement: superficial only.

ECOG PERFORMANCE STATUS: 0

UPDATED STAGING:
Primary tumor: T2 (2.3cm)
Regional nodes: N1 (1-3 axillary nodes positive on PET)
Distant metastasis: M0 (no distant disease)
FINAL CLINICAL STAGE: IIB (cT2N1M0)

TREATMENT DISCUSSION:
Discussed neoadjuvant chemotherapy approach.
Goal: downstage disease, assess treatment response,
breast conservation potentially achievable.
Regimen: Dose Dense AC x 4 cycles followed by
Paclitaxel weekly x 12 weeks.

MEDICATIONS STARTED TODAY:
1. Ondansetron 8mg — antiemetic pre-chemotherapy
2. Dexamethasone 12mg — pre-chemotherapy
3. Loratadine 10mg — allergy prophylaxis
(Existing medications continued)

PLAN:
1. Start neoadjuvant chemotherapy next week
2. Cycle 1 Day 1: Doxorubicin 60mg/m2 +
   Cyclophosphamide 600mg/m2 q2weeks x 4 cycles
3. Then Paclitaxel 80mg/m2 weekly x 12
4. Repeat imaging after 4 cycles to assess response
5. Surgery planning after completion of chemotherapy
6. Return in 3 weeks for Cycle 1 assessment

PHYSICIAN SIGNATURE: Dr. Amanda Singh (SYNTHETIC)